0
0
February 15, 2025 – A groundbreaking international clinical trial led by a researcher from Mount Sinai has revealed that sotagliflozin, a newly FDA-approved medication for type 2 diabetes and kidney disease with cardiovascular risk factors, significantly reduces heart attacks and strokes.
Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor that uniquely blocks two proteins—SGLT1 and SGLT2—responsible for glucose and sodium transport across cell membranes. Unlike other SGLT2 inhibitors, sotagliflozin’s additional inhibition of SGLT1 contributes to its superior cardiovascular benefits.
The findings, published in The Lancet Diabetes & Endocrinology, mark a historic milestone as the first evidence of an SGLT inhibitor reducing major adverse cardiovascular events. These results suggest that sotagliflozin could see wider adoption in preventing fatal cardiovascular incidents worldwide.
“These results demonstrate a new mechanism of action—combined blockade with sotagliflozin of the SGLT1 receptors (found in the kidney, gut, heart, and brain) and SGLT2 receptors (found in the kidney)—to reduce heart attack and stroke risk,” said Dr. Deepak L. Bhatt, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai.
A large-scale, randomized, multicenter trial called SCORED evaluated sotagliflozin’s impact on life-threatening cardiovascular outcomes. The study enrolled 10,584 patients with chronic kidney disease, type 2 diabetes, and additional cardiovascular risk factors. Participants were randomly assigned either sotagliflozin or a placebo and were monitored for an average of 16 months.
The results showed a 23% reduction in heart attack, stroke, and cardiovascular-related deaths among patients taking sotagliflozin compared to those on a placebo.
“Physicians now have a new option to reduce global cardiovascular risk such as heart failure, progression of kidney disease, heart attack, and stroke in patients with either heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors,” Dr. Bhatt added.
“This drug was approved to reduce the risk of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent heart failure visits for patients with either heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. These important, new data show that it additionally reduces the risk of heart attacks and strokes, and we could see more widespread use as a result.”
Disclaimer:
This article is for informational purposes only and does not constitute medical advice. Readers are encouraged to consult their healthcare providers before making any changes to their medication or treatment plans.
